Beyond Cancer, an affiliate of Beyond Air (XAIR), announced the appointment of Gavin Choy, PharmD as Chief Operating Officer. He brings more than 20 years of expertise to Beyond Cancer in the development of small molecules as well as immunotherapy in oncology with the successful management of multiple early first-in-human studies in the U.S. and Australia/New Zealand, and late-stage registrational clinical studies globally, as well as early access, and compassionate use programs. Dr. Choy most recently served as Chief Clinical Development Officer at GT Biopharma (GTBP).
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on XAIR:
- Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer
- Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board
- Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast
- Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases
- Beyond Cancer announces publication of pre-clinical data on tumor ablation tech